West Pharmaceutical Services, Inc.

WST · NYSE · USD

Can HVP Components keep growing in the high teens on biologics wins, Annex 1 upgrades and GLP-1 volume, or do plant capacity and a concentrated customer base cap the growth?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Component upgrades lift mix

    The bull case is that West's highest-value elastomer components keep replacing standard ones on drugs already on the market, lifting revenue and margin from the same volume.

  • Biologics specification wins

    West is written into the drug master file for most new biologics, so each approval adds component demand that customers rarely move to a competing supplier.

  • Injectable obesity drug volumes

    Management argues oral obesity drugs expand rather than replace the injectable market, so demand for stoppers, plungers and seals keeps compounding as adoption grows.

  • European plant productivity

    Operating improvements at the European plants are lifting output from equipment already installed, which lets West serve demand it previously could not fill.

Bear case

  • Plant capacity limits growth

    The bear case is that West can only grow as fast as it can hire, train and qualify extra plant capacity, and demand has been running ahead of supply.

  • Customer concentration

    A few large pharmaceutical customers and contract programs supply a big share of sales, and one contract exit already removes meaningful revenue next year.

  • Oral obesity drug competition

    If oral obesity drugs take share from injectables, West's fastest-growing component franchise would face a smaller market than the current plan assumes.

  • Cost inflation

    Rising oil and commodity costs, plus heavier research spending, have kept operating margin gains well behind the improvement in gross margin.

Bull and bear points

Growth & Execution

In short: HVP components are growing quickly, but plant capacity and a contract exit cap growth.

Bull · 2

  • Non-GLP-1 components lead the quarter

    Revenue rose 13.8% in the quarter, with non-GLP-1 HVP components up in the high teens and the largest contributor to the outperformance, so growth is broadening beyond obesity drugs.

    Q2 FY2026 call

  • Outlook raised twice this year

    Three months ago management guided to mid single digit organic growth for 2026 and called the plan prudent; it now expects 10% to 11% organic growth and earnings of $8.85 to $9.05 a share.

    Tone shiftQ4 FY2025 → Q2 FY2026
Bear · 2

  • Plant capacity limits how fast sales grow

    Management says demand has run ahead of supply and that qualifying a second manufacturing site takes six to twelve months, so sales growth depends on hiring and line transfers.

    Q1 FY2026 call

  • Contract manufacturing loses a program

    The CGM contract ends in mid-2026, a roughly $40 million second-half headwind, and replacement customers for the Dublin space have not yet been signed.

    Q1 FY2026 call

Profitability & Financial Strength

In short: Product mix is lifting gross margin, while research spending and input costs absorb much of the gain.

Bull · 2

  • HVP mix lifts gross margin two points

    Gross margin reached 37.7% as higher-value components ran through plants already built, so each extra unit of volume drops to profit at a high rate.

    Q2 FY2026 call

  • Buyback replaces a wait-and-see policy

    Nine months ago the new finance chief said West had to define a capital policy; it has since authorized a $1 billion buyback and returned $517 million to shareholders in a year.

    Tone shiftQ3 FY2025 → Q1 FY2026
Bear · 2

  • Operating margin trails the gross margin gain

    Gross margin rose 2.0 points in the second quarter while operating margin rose only 0.5, as research spending and incentive pay took the difference.

    Q4 FY2025 call

  • Oil and commodity costs remain a drag

    Management expects a single-digit-million net cost from higher oil and commodity prices after mitigation, so input inflation is a recurring item that pricing has to keep covering.

    Q1 FY2026 call

Market Position

In short: West supplies most new biologics and benefits from Annex 1 rules, but a few customers dominate revenue.

Bull · 2

  • Most new biologics specify West parts

    Over 90% of new biologics use West components, and once a customer references West's drug master file, changing suppliers is slow and costly, which protects future revenue.

    Q4 FY2025 call

  • Annex 1 demand spreads past Europe

    Annex 1 was framed as a European regulatory driver; management now says U.S. audit findings are pushing American drugmakers to upgrade, widening the pool of components to convert.

    Tone shiftQ3 FY2025 → Q2 FY2026
Bear · 2

  • Revenue rests on a few drugmakers

    A limited number of customers account for a substantial share of sales, so a lost contract or a hard pricing negotiation with one of them moves total company results.

    10-K, filed 2026-02-17

  • Oral obesity drugs could shrink injectables

    Oral obesity drugs are now on the market, and West's component volumes assume injectable pens, vials and auto-injectors stay the dominant format for these therapies.

    10-K, filed 2026-02-17